<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39451427</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9032</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Healthcare (Basel, Switzerland)</Title><ISOAbbreviation>Healthcare (Basel)</ISOAbbreviation></Journal><ArticleTitle>Differences in the Rates of Diagnoses of Mental and Behavioral Disorders Due to Psychoactive Substance Use by Sex and Age during Pre-Pandemic and COVID-19 Pandemic Periods in Kazakhstan.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2012</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/healthcare12202012</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic had profound impacts worldwide on individuals with mental and behavioral disorders, including disorders due to psychoactive substance use. We investigated how the COVID-19 pandemic affected the trends in these disorders in the Republic of Kazakhstan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We researched and compared ICD-10 data on mental and behavioral disorders due to substance use in Kazakhstan that were diagnosed in 2018-2019 (pre-pandemic) versus 2020-2021 (the pandemic period).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The data for the pandemic period were significantly different from those of the pre-pandemic in that (<i>i</i>) 'other stimulant-related disorders (F15)' and 'other psychoactive substance-related disorders (F19)' were increased in the younger age groups, (<i>ii</i>) the risk of 'opioid-related disorders (F11)' was decreased in the 30-year-old group in both males and females, and (<i>iii</i>) the risk of 'alcohol-related disorders (F10)' was increased in the 30-year-old group and decreased in the 20- and 50-year-old groups. In only the males, (<i>iv</i>) the risk of 'other psychoactive substance-related disorders (F19)' was increased in almost all of the age groups, and (<i>v</i>) the risk of 'cannabis-related disorders (F12)' was increased in the ≥50-year-olds. The pre-pandemic and pandemic periods thus involved changes due to COVID-19 in both males and females that were especially notable in males.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that further measures designed to prevent mental and behavioral disorders due to psychoactive substances are necessary at the primary, secondary, and tertiary levels, and personnel in medicine/nursing, the government, private organizations, and the public need to collaborate to devise such measures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akkuzinova</LastName><ForeName>Kamila</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6294-4168</Identifier><AffiliationInfo><Affiliation>Board, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Ken</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0710-481X</Identifier><AffiliationInfo><Affiliation>Research and Education Faculty, Medical Sciences Cluster, Health Service Center, Kochi University, Kochi 780-8520, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toleuov</LastName><ForeName>Elaman</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0005-0112-3744</Identifier><AffiliationInfo><Affiliation>Board, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moldagaliyev</LastName><ForeName>Timur</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4385-8459</Identifier><AffiliationInfo><Affiliation>Board, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seksenbayev</LastName><ForeName>Nursultan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6276-3546</Identifier><AffiliationInfo><Affiliation>Board, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamedinova</LastName><ForeName>Ulzhan</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-1671-289X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ospanova</LastName><ForeName>Nargul</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9316-6389</Identifier><AffiliationInfo><Affiliation>Board, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyussupov</LastName><ForeName>Altay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0875-1020</Identifier><AffiliationInfo><Affiliation>Board, Semey Medical University, Semey 071400, Kazakhstan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21K02383</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Healthcare (Basel)</MedlineTA><NlmUniqueID>101666525</NlmUniqueID><ISSNLinking>2227-9032</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">Kazakhstan</Keyword><Keyword MajorTopicYN="N">age</Keyword><Keyword MajorTopicYN="N">difference</Keyword><Keyword MajorTopicYN="N">female</Keyword><Keyword MajorTopicYN="N">male</Keyword><Keyword MajorTopicYN="N">mental and behavioral disorders due to psychoactive substance use</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39451427</ArticleId><ArticleId IdType="pmc">PMC11506856</ArticleId><ArticleId IdType="doi">10.3390/healthcare12202012</ArticleId><ArticleId IdType="pii">healthcare12202012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO)  International Statistical Classification of Diseases and Related Health Problems 10th Revision.  [(accessed on 10 June 2024)].  Available online:  https://icd.who.int/browse10/2019/en#/F10-F19.</Citation></Reference><Reference><Citation>World Health Organization (WHO)  International Classification of Diseases Eleventh Revision (ICD-11)  [(accessed on 10 June 2024)].  Available online:  https://icd.who.int/browse/2024-01/mms/en#1602669465.</Citation></Reference><Reference><Citation>American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. 5th ed. American Psychiatric Association Publishing; Washington, DC, USA: 2022. pp. 546–553. Text Revision.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.books.9780890425596</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaldelli-Maia J.M., Bhugra D. Analysis of Global Prevalence of Mental and Substance Use Disorders within Countries: Focus on Sociodemographic Characteristics and Income Levels. Int. Rev. Psychiatry. 2022;34:6–15. doi: 10.1080/09540261.2022.2040450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540261.2022.2040450</ArticleId><ArticleId IdType="pubmed">35584016</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)   Global Status Report on Alcohol and Health 2018. World Health Organization; Genève, Switzerland: 2018.  [(accessed on 10 June 2024)]. pp. 13–15. Available online:  https://iris.who.int/bitstream/handle/10665/274603/9789241565639-eng.pdf.</Citation></Reference><Reference><Citation>United Nations Office on Drugs and Crime  . World Drug Report 2020. Volume E.20.XI.6. United Nations Publication; Vienna, Austria: 2020.  [(accessed on 10 June 2024)]. Executive Summary/Impact of COVID-19/Policy implications; pp. 7–28. Available online:  https://wdr.unodc.org/wdr2020/field/WDR20_BOOKLET_1.pdf.</Citation></Reference><Reference><Citation>United Nations Office on Drugs and Crime  . World Drug Report 2021. Volume E.21.XI.8. United Nations Publication; Vienna, Austria: 2020.  [(accessed on 10 June 2024)]. Executive summary/Policy implications; pp. 12–20. Available online:  https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf.</Citation></Reference><Reference><Citation>Peacock A., Leung J., Larney S., Colledge S., Hickman M., Rehm J., Giovino G.A., West R., Hall W., Griffiths P., et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113:1905–1926. doi: 10.1111/add.14234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/add.14234</ArticleId><ArticleId IdType="pubmed">29749059</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2019 Tobacco Collaborators Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397:2337–2360. doi: 10.1016/S0140-6736(21)01169-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01169-7</ArticleId><ArticleId IdType="pmc">PMC8223261</ArticleId><ArticleId IdType="pubmed">34051883</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Regional Office for Europe  . A Timeline of WHO’s COVID-19 Response in the WHO European Region: A Living Document (Version 3.0, from 31 December 2019 to 31 December 2021) WHO Regional Office for Europe; Copenhagen, Denmark: 2022.  [(accessed on 10 June 2024)]. pp. 5–115. Available online:  https://iris.who.int/bitstream/handle/10665/351782/WHO-EURO-2022-1772-41523-63024-eng.pdf.</Citation></Reference><Reference><Citation>Wei Y., Shah R. Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. Pharmaceuticals. 2020;13:155. doi: 10.3390/ph13070155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph13070155</ArticleId><ArticleId IdType="pmc">PMC7407364</ArticleId><ArticleId IdType="pubmed">32708495</ArticleId></ArticleIdList></Reference><Reference><Citation>Both L.M., Zoratto G., Calegaro V.C., Ramos-Lima L.F., Negretto B.L., Hauck S., Freitas L.H.M. COVID-19 pandemic and social distancing: Economic, psychological, family, and technological effects. Trends Psychiatry Psychother. 2021;43:85–91. doi: 10.47626/2237-6089-2020-0085.</Citation><ArticleIdList><ArticleId IdType="doi">10.47626/2237-6089-2020-0085</ArticleId><ArticleId IdType="pmc">PMC8317552</ArticleId><ArticleId IdType="pubmed">34043896</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Excess Mortality Collaborators Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–2021. Lancet. 2022;399:1513–1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey S., Biswas P., Ghosh R., Chatterjee S., Dubey M., Chatterjee S., Lahiri D., Lavie C. Psychosocial impact of COVID-19. Diabetes Metab. Syndr. 2020;14:779–788. doi: 10.1016/j.dsx.2020.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.05.035</ArticleId><ArticleId IdType="pmc">PMC7255207</ArticleId><ArticleId IdType="pubmed">32526627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo H.X., Li W., Yang Y., Wang Y., Zhang Q., Cheung T., Wu X., Xiang Y.T. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychol. Med. 2021;51:1052–1053. doi: 10.1017/S0033291720000999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291720000999</ArticleId><ArticleId IdType="pmc">PMC7200846</ArticleId><ArticleId IdType="pubmed">32216863</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J., Lipsitz O., Nasri F., Lui L.M.W., Gill H., Phan L., Chen-Li D., Iacobucci M., Ho R., Majeed A., et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J. Affect. Disord. 2020;277:55–64. doi: 10.1016/j.jad.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7413844</ArticleId><ArticleId IdType="pubmed">32799105</ArticleId></ArticleIdList></Reference><Reference><Citation>Maye C.E., Wojcik K.D., Candelari A.E., Goodman W.K., Storch E.A. Obsessive compulsive disorder during the COVID-19 pandemic: A brief review of course, psychological assessment and treatment considerations. J. Obs. Compuls. Relat. Disord. 2022;33:100722. doi: 10.1016/j.jocrd.2022.100722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocrd.2022.100722</ArticleId><ArticleId IdType="pmc">PMC8855616</ArticleId><ArticleId IdType="pubmed">35194549</ArticleId></ArticleIdList></Reference><Reference><Citation>Garey L., Olofsson H., Garza T., Rogers A., Kauffman B., Zvolensky M. Directional Effects of Anxiety and Depressive Disorders with Substance Use: A Review of Recent Prospective Research. Curr. Addict. Rep. 2020;7:344–355. doi: 10.1007/s40429-020-00321-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40429-020-00321-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R., Farquharson L., Rhodes E., Dang M., Butler J., Quirk A., Baldwin D.S., Crawford M.J. Impact of Substance Use Disorder on Quality of Inpatient Mental Health Services for People with Anxiety and Depression. J. Dual. Diagn. 2021;17:80–93. doi: 10.1080/15504263.2020.1825892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15504263.2020.1825892</ArticleId><ArticleId IdType="pubmed">33048661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjork J.M., Nicholas D.T. Stress and Substance Misuse. In: Moeller G., Terplan M., editors. Substance Use Disorders. 1st ed. Volume 6. Oxford University Press; Oxford, UK: 2020. pp. 101–118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/MED/9780190920197.003.0006</ArticleId></ArticleIdList></Reference><Reference><Citation>Clair R., Gordon M., Kroon M., Reilly C. The effects of social isolation on well-being and life satisfaction during pandemic. Humanit. Soc. Sci. Commun. 2021;8:28. doi: 10.1057/s41599-021-00710-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1057/s41599-021-00710-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie N., Vojvodic V., Monterosso J. The Early Impact of Social Distancing Measures on Drug Use. Subst. Use Misuse. 2021;56:997–1004. doi: 10.1080/10826084.2021.1901934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10826084.2021.1901934</ArticleId><ArticleId IdType="pubmed">33784957</ArticleId></ArticleIdList></Reference><Reference><Citation>Layman H.M., Thorisdottir I.E., Halldorsdottir T., Sigfusdottir I.D., Allegrante J.P., Kristjansson A.L. Substance Use Among Youth During the COVID-19 Pandemic: A Systematic Review. Curr. Psychiatry Rep. 2022;24:307–324. doi: 10.1007/s11920-022-01338-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-022-01338-z</ArticleId><ArticleId IdType="pmc">PMC9043089</ArticleId><ArticleId IdType="pubmed">35476186</ArticleId></ArticleIdList></Reference><Reference><Citation>Deimel D., Firk C., Stöver H., Hees N., Scherbaum N., Fleißner S. Substance Use and Mental Health during the First COVID-19 Lockdown in Germany: Results of a Cross-Sectional Survey. Int. J. Environ. Res. Public Health. 2022;19:12801. doi: 10.3390/ijerph191912801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912801</ArticleId><ArticleId IdType="pmc">PMC9566226</ArticleId><ArticleId IdType="pubmed">36232097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugaya N., Yamamoto T., Suzuki N., Uchiumi C. Alcohol Use and Its Related Psychosocial Effects during the Prolonged COVID-19 Pandemic in Japan: A Cross-Sectional Survey. Int. J. Environ. Res. Public Health. 2021;18:13318. doi: 10.3390/ijerph182413318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182413318</ArticleId><ArticleId IdType="pmc">PMC8707504</ArticleId><ArticleId IdType="pubmed">34948939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q.Q., Kaelber D.C., Xu R., Volkow N.D. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol. Psychiatry. 2021;26:30–39. doi: 10.1038/s41380-020-00880-7. Erratum in Mol. Psychiatry 2021, 26, 40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00880-7</ArticleId><ArticleId IdType="pmc">PMC7488216</ArticleId><ArticleId IdType="pubmed">32929211</ArticleId></ArticleIdList></Reference><Reference><Citation>Baillargeon J., Polychronopoulou E., Kuo Y.F., Raji M.A. The Impact of Substance Use Disorder on COVID-19 Outcomes. Psychiatr. Serv. 2021;72:578–581. doi: 10.1176/appi.ps.202000534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ps.202000534</ArticleId><ArticleId IdType="pmc">PMC8089118</ArticleId><ArticleId IdType="pubmed">33138712</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhoudian A., Baldacchino A., Clark N., Gerra G., Ekhtiari H., Dom G., Mokri A., Sadeghi M., Nematollahi P., Demasi M., et al. COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper. Basic Clin. Neurosci. 2020;11:133–150. doi: 10.32598/bcn.11.covid19.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.32598/bcn.11.covid19.1</ArticleId><ArticleId IdType="pmc">PMC7368103</ArticleId><ArticleId IdType="pubmed">32855772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jemberie W.B., Stewart Williams J., Eriksson M., Grönlund A.S., Ng N., Blom Nilsson M., Padyab M., Priest K.C., Sandlund M., Snellman F., et al. Substance Use Disorders and COVID-19: Multi-Faceted Problems Which Require Multi-Pronged Solutions. Front. Psychiatry. 2020;11:714. doi: 10.3389/fpsyt.2020.00714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.00714</ArticleId><ArticleId IdType="pmc">PMC7396653</ArticleId><ArticleId IdType="pubmed">32848907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ornell F., Moura H.F., Scherer J.N., Pechansky F., Kessler F.H.P., von Diemen L. The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment. Psychiatry Res. 2020;289:113096. doi: 10.1016/j.psychres.2020.113096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113096</ArticleId><ArticleId IdType="pmc">PMC7219362</ArticleId><ArticleId IdType="pubmed">32405115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Park S., Jang S.N., Reyes K.A., Garcia F.J., Canila C., Oraño J., Ballesteros A.J., Muhartini T., Frans S., et al. Differential impacts of health systems and sociocultural environment on vulnerable populations during the COVID-19 pandemic: Lessons from four Asia-Pacific countries. BMC Public Health. 2024;24:1501. doi: 10.1186/s12889-024-18949-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-024-18949-1</ArticleId><ArticleId IdType="pmc">PMC11151645</ArticleId><ArticleId IdType="pubmed">38840230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola L., Kohrt B.A., Hanlon C., Naslund J.A., Sikander S., Balaji M., Benjet C., Cheung E.Y.L., Eaton J., Gonsalves P., et al. COVID-19 mental health impact and responses in low-income and middle-income countries: Reimagining global mental health. Lancet Psychiatry. 2021;8:535–550. doi: 10.1016/S2215-0366(21)00025-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00025-0</ArticleId><ArticleId IdType="pmc">PMC9764935</ArticleId><ArticleId IdType="pubmed">33639109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Janmohamed K., Nyhan K., Martins S.S., Cerda M., Hasin D., Scott J., Sarpong Frimpong A., Pates R., Ghandour L.A., et al. Substance, use in relation to COVID-19: A scoping review. Addict. Behav. 2022;127:107213. doi: 10.1016/j.addbeh.2021.107213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addbeh.2021.107213</ArticleId><ArticleId IdType="pmc">PMC8684053</ArticleId><ArticleId IdType="pubmed">34959077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaeiahari M., Fairman B.J. Impact of COVID-19 on the characteristics of opioid overdose deaths in Arkansas. Int. J. Drug Policy. 2022;109:103836. doi: 10.1016/j.drugpo.2022.103836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugpo.2022.103836</ArticleId><ArticleId IdType="pmc">PMC9376304</ArticleId><ArticleId IdType="pubmed">36027767</ArticleId></ArticleIdList></Reference><Reference><Citation>White A.M., Castle I.P., Powell P.A., Hingson R.W., Koob G.F. Alcohol-Related Deaths During the COVID-19 Pandemic. JAMA. 2022;327:1704–1706. doi: 10.1001/jama.2022.4308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.4308</ArticleId><ArticleId IdType="pmc">PMC8933830</ArticleId><ArticleId IdType="pubmed">35302593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Lui L.M.W., Brietzke E., Liao Y., Lu C., Ho R., Subramaniapillai M., Mansur R.B., Rosenblat J.D., McIntyre R.S. Comparing mortality from COVID-19 to mortality due to overdose: A micromort analysis. J. Affect. Disord. 2022;296:514–521. doi: 10.1016/j.jad.2021.09.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.09.059</ArticleId><ArticleId IdType="pmc">PMC8461265</ArticleId><ArticleId IdType="pubmed">34656039</ArticleId></ArticleIdList></Reference><Reference><Citation>López-Pelayo H., Aubin H.J., Drummond C., Dom G., Pascual F., Rehm J., Saitz R., Scafato E., Gual A. “The post-COVID era”: Challenges in the treatment of substance use disorder (SUD) after the pandemic. BMC Med. 2020;18:241. doi: 10.1186/s12916-020-01693-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01693-9</ArticleId><ArticleId IdType="pmc">PMC7392642</ArticleId><ArticleId IdType="pubmed">32731868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochstatter K.R., Akhtar W.Z., Dietz S., Pe-Romashko K., Gustafson D.H., Shah D.V., Krechel S., Liebert C., Miller R., El-Bassel N., et al. Potential Influences of the COVID-19 Pandemic on Drug Use and HIV Care Among People Living with HIV and Substance Use Disorders: Experience from a Pilot mHealth Intervention. AIDS Behav. 2021;25:354–359. doi: 10.1007/s10461-020-02976-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-020-02976-1</ArticleId><ArticleId IdType="pmc">PMC7376523</ArticleId><ArticleId IdType="pubmed">32705370</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy P., Narasimha V.L. Effects of the COVID-19 pandemic and lockdown on alcohol use disorders and complications. Curr. Opin. Psychiatry. 2021;34:376–385. doi: 10.1097/YCO.0000000000000720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000720</ArticleId><ArticleId IdType="pmc">PMC8183243</ArticleId><ArticleId IdType="pubmed">34016817</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitta K., Naito H., Tabuchi T., Kakiuchi Y. Fear of COVID-19 and illicit drug use during COVID-19 pandemic in Japan: A case-control study. PeerJ. 2024;12:e18137. doi: 10.7717/peerj.18137.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.18137</ArticleId><ArticleId IdType="pmc">PMC11439375</ArticleId><ArticleId IdType="pubmed">39346045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisneros I.E., Cunningham K.A. Covid-19 interface with drug misuse and substance use disorders. Neuropharmacology. 2021;198:108766. doi: 10.1016/j.neuropharm.2021.108766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2021.108766</ArticleId><ArticleId IdType="pmc">PMC8388132</ArticleId><ArticleId IdType="pubmed">34454912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman B.G., Kelly J.F. Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond. J. Subst. Abuse Treat. 2021;120:108152. doi: 10.1016/j.jsat.2020.108152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsat.2020.108152</ArticleId><ArticleId IdType="pmc">PMC7532989</ArticleId><ArticleId IdType="pubmed">33129636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan K., Tomar S. COVID-19 and Supply Chain Disruption: Evidence from Food Markets in India. Am. J. Agric. Econ. 2021;103:35–52. doi: 10.1111/ajae.12158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajae.12158</ArticleId><ArticleId IdType="pmc">PMC7675588</ArticleId><ArticleId IdType="pubmed">33230345</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvanta C., Caban-Martinez A.J., Cabral N., Ball C.K., Moore K.G., Eastlake A., Levin J.L., Nessim D.E., These M.S., Schulte P.A. In Search of a Value Proposition for COVID-19 Testing in the Work Environment: A Social Marketing Analysis. Int. J. Environ. Res. Public Health. 2022;19:12496. doi: 10.3390/ijerph191912496.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912496</ArticleId><ArticleId IdType="pmc">PMC9566354</ArticleId><ArticleId IdType="pubmed">36231794</ArticleId></ArticleIdList></Reference><Reference><Citation>Norström T., Ramstedt M. The impact of the COVID-19 pandemic on mortality in Sweden—Did it differ across socioeconomic groups? Eur. J. Epidemiol. 2024;39:137–145. doi: 10.1007/s10654-023-01068-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-023-01068-3</ArticleId><ArticleId IdType="pmc">PMC10904510</ArticleId><ArticleId IdType="pubmed">38177570</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva L.T., Modesto A.C.F., Amaral R.G., Lopes F.M. Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage. Eur. J. Clin. Pharmacol. 2022;78:435–466. doi: 10.1007/s00228-021-03238-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-021-03238-2</ArticleId><ArticleId IdType="pubmed">34716774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakaloudi D.R., Evripidou K., Jayawardena R., Breda J., Dardavessis T., Poulia K.A., Chourdakis M. The Impact of Lockdowns on Caffeine Consumption: A Systematic Review of the Evidence. Int. J. Environ. Res. Public Health. 2022;19:5255. doi: 10.3390/ijerph19095255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19095255</ArticleId><ArticleId IdType="pmc">PMC9102419</ArticleId><ArticleId IdType="pubmed">35564647</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes S., Sosa-Napolskij M., Lobo G., Silva I. Impact of the COVID-19 pandemic in the Portuguese population: Consumption of alcohol, stimulant drinks, illegal substances, and pharmaceuticals. PLoS ONE. 2021;16:e0260322. doi: 10.1371/journal.pone.0260322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260322</ArticleId><ArticleId IdType="pmc">PMC8604309</ArticleId><ArticleId IdType="pubmed">34797874</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy K., Wachtel L., Friedman T. The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? J. Subst. Abuse Treat. 2021;131:108394. doi: 10.1016/j.jsat.2021.108394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsat.2021.108394</ArticleId><ArticleId IdType="pmc">PMC8032399</ArticleId><ArticleId IdType="pubmed">34098292</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia G.P., Stringfellow E.J., DiGennaro C., Poellinger N., Wood J., Wakeman S., Jalali M.S. Opioid overdose decedent characteristics during COVID-19. Ann. Med. 2022;54:1081–1088. doi: 10.1080/07853890.2022.2067350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2067350</ArticleId><ArticleId IdType="pmc">PMC9045762</ArticleId><ArticleId IdType="pubmed">35467475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarfraz A., Sarfraz Z., Sarfraz M., Thevuthasan S., Khan T., Inam I., Pandav K., Fatima F., Patel G., Baralt D., et al. The Incidence of Alcohol Use Disorders during the COVID-19 Pandemic. Psychiatr. Danub. 2022;34:535–543. doi: 10.24869/psyd.2022.535.</Citation><ArticleIdList><ArticleId IdType="doi">10.24869/psyd.2022.535</ArticleId><ArticleId IdType="pubmed">36257004</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigsby T.J., Howard K., Howard J.T., Perrotte J. COVID-19 Concerns, Perceived Stress, and Increased Alcohol Use Among Adult Women in the United States. Clin. Nurs. Res. 2023;32:84–93. doi: 10.1177/10547738221136678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10547738221136678</ArticleId><ArticleId IdType="pmc">PMC9679311</ArticleId><ArticleId IdType="pubmed">36398789</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfora A., Petrella R., Ambrosio G., Fracassi I., Festinese S., Feola A., Campobasso C.P. Toxicological Analysis of Illicit Drugs Seized in Naples (Italy) and First Detection of Synthetic Cannabinoids during COVID-19 Pandemic. Healthcare. 2022;10:1488. doi: 10.3390/healthcare10081488.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10081488</ArticleId><ArticleId IdType="pmc">PMC9408475</ArticleId><ArticleId IdType="pubmed">36011145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage S.H., Hickman M., Zammit S. Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biol. Psychiatry. 2016;79:549–556. doi: 10.1016/j.biopsych.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2015.08.001</ArticleId><ArticleId IdType="pubmed">26386480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafaye G., Karila L., Blecha L., Benyamina A. Cannabis, cannabinoids, and health. Dialogues Clin. Neurosci. 2017;19:309–316. doi: 10.31887/DCNS.2017.19.3/glafaye.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2017.19.3/glafaye</ArticleId><ArticleId IdType="pmc">PMC5741114</ArticleId><ArticleId IdType="pubmed">29302228</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate B.B., Kassie A.M., Kassaw M.W., Aragie T.G., Masresha S.A. Sex difference in coronavirus disease (COVID-19): A systematic review and meta-analysis. BMJ Open. 2020;10:e040129. doi: 10.1136/bmjopen-2020-040129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-040129</ArticleId><ArticleId IdType="pmc">PMC7539579</ArticleId><ArticleId IdType="pubmed">33028563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng P., Liu Y., Yang W.F., Chen S., Wang Y., Yang Q., Li M., Wang Y., Hao Y., et al. Gender differences in alcohol abuse/dependence among medical undergraduates during the post-COVID 19 pandemic period (October 20, 2020–April 5, 2021) in China. BMC Psychiatry. 2023;23:753. doi: 10.1186/s12888-023-05260-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-023-05260-3</ArticleId><ArticleId IdType="pmc">PMC10577989</ArticleId><ArticleId IdType="pubmed">37845643</ArticleId></ArticleIdList></Reference><Reference><Citation>Babicki M. Use of Alcohol, Cannabinoids, Psychostimulants, and Sedatives before and during the COVID-19 Pandemic among Students in 40 European Countries. Int. J. Environ. Res. Public Health. 2022;19:14879. doi: 10.3390/ijerph192214879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192214879</ArticleId><ArticleId IdType="pmc">PMC9690623</ArticleId><ArticleId IdType="pubmed">36429598</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue K., Hashioka S., Takeshita H., Fujita Y., Moriwaki S., Murayama Y., Fujita Y., Matsumoto H., Takeichi N., Hoshi M., et al. Drug offenses in the Tokyo Metropolitan Area: Trends for 2016–2018. Leg. Med. 2020;47:101739. doi: 10.1016/j.legalmed.2020.101739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.legalmed.2020.101739</ArticleId><ArticleId IdType="pubmed">32645558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasshauer J.M., Bollmann A., Hohenstein S., Hindricks G., Meier-Hellmann A., Kuhlen R., Broocks A., Schomerus G., Steng ler K. Emergency hospital admissions for psychiatric disorders in a German-wide hospital network during the COVID-19 outbreak. Soc. Psychiatry Psychiatr. Epidemiol. 2021;56:1469–1475. doi: 10.1007/s00127-021-02091-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00127-021-02091-z</ArticleId><ArticleId IdType="pmc">PMC8053025</ArticleId><ArticleId IdType="pubmed">33866383</ArticleId></ArticleIdList></Reference><Reference><Citation>Descamps A., Frenkiel J., Zarca K., Laidi C., Godin O., Launay O., Leboyer M., Durand-Zaleski I. Association between mental disorders and COVID-19 outcomes among inpatients in France: A retrospective nationwide population-based study. J. Psychiatr. Res. 2022;155:194–201. doi: 10.1016/j.jpsychires.2022.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2022.08.019</ArticleId><ArticleId IdType="pmc">PMC9392549</ArticleId><ArticleId IdType="pubmed">36063611</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>